Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33024
Title: Tau in dementia with Lewy bodies.
Austin Authors: Chin, Kai Sin;Churilov, Leonid ;Doré, Vincent ;Villemagne, Victor L ;Rowe, Christopher C ;Yassi, Nawaf;Watson, Rosie
Affiliation: Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia
Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
Molecular Imaging and Therapy
Medicine (University of Melbourne)
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
Department of Aged Care, The Royal Melbourne Hospital, Parkville, VIC, Australia
Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Clayton South, VIC, Australia
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Issue Date: Feb-2024
Date: 2023
Publication information: The Australian and New Zealand Journal of Psychiatry 2024-02; 58(2)
Abstract: Neurofibrillary tangles are present in a proportion of people with dementia with Lewy bodies and may be associated with worse cognition. Recent advances in biomarkers for Alzheimer's disease include second-generation tau positron emission tomography as well as the detection of phosphorylated tau at threonine 181 (p-tau181) in plasma. This study aimed to investigate tau in people with dementia with Lewy bodies using a second-generation tau positron emission tomography tracer as well as plasma p-tau181. Twenty-seven participants (mean age 74.7 ± 5.5) with clinically diagnosed probable dementia with Lewy bodies underwent comprehensive clinical assessment and positron emission tomography imaging (18F-MK6240 and 18F-NAV4694). Plasma p-tau181 levels were measured using Simoa technology. Five dementia with Lewy bodies participants (18.5%) had an abnormal tau positron emission tomography (increased tau uptake in the temporal meta-region-of-interest). Higher plasma p-tau181 concentrations correlated with higher tau deposition in the temporal region (ρ = 0.46, 95% confidence interval = [0.10, 0.72]) and classified abnormal tau positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.95 (95% confidence interval = [0.86, 0.99]). Plasma p-tau181 also correlated positively with cortical amyloid-beta binding (ρ = 0.68, 95% confidence interval = [0.40, 0.84]) and classified abnormal amyloid-beta positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.91 (95% confidence interval = [0.79, 0.99]). There was no association found between tau deposition and any of the clinical variables. Tau is a common co-pathology in dementia with Lewy bodies. Plasma p-tau181 correlated with abnormal tau and amyloid-beta positron emission tomography and may potentially be used as a marker to identify co-morbid Alzheimer's disease-related pathology in dementia with Lewy bodies. The clinical implications of tau in dementia with Lewy bodies need to be further evaluated in larger longitudinal studies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33024
DOI: 10.1177/00048674231177219
ORCID: 0000-0002-3384-3499
Journal: The Australian and New Zealand Journal of Psychiatry
Start page: 48674231177219
PubMed URL: 37264610
ISSN: 1440-1614
Type: Journal Article
Subjects: Alzheimer’s disease
Tau
dementia with Lewy bodies
phosphorylated tau
positron emission tomography
Appears in Collections:Journal articles

Show full item record

Page view(s)

70
checked on Nov 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.